Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...

MabThera shown to be effective and well tolerated over the long-term A study has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in their ...

Basel, 15 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus ...

San Diego, U.S.A.: Roche today announced positive results of the Phase III REFLEX study, evaluating the efficacy and safety of MabThera in patients with rheumatoid arthritis (RA), who have had an ...

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing symptoms ...

Roche has received a positive recommendation from Europe's scientific advisory board for the use of MabThera (rituximab) as maintenance therapy for patients with relapsed or refractory follicular ...

Even more patients in England and Wales are set to have access to Roche’s MabThera after it won backing as a treatment for two potentially fatal forms of blood vessel inflammation. Final draft ...

New hope for patients with most common form of leukaemia in adults Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved MabThera (rituximab) for use in patients ...

Roche Holdings AGRHHBY announced that the European Commission has approved a label expansion of its rheumatoid arthritis (RA) drug, MabThera. The drug is now approved in Europe for the treatment of ...

Roche’s MabThera is now available for mainstream use on the NHS in England and Wales to treat a rare autoimmune condition after receiving definitive backing from their cost-effectiveness watchdog. The ...

We conducted a double-blind, parallel-group study in patients with untreated DLBCL who were eligible to receive cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy. Patients were ...

NICE had previously recommended MabThera in combination with CVP for this indication, and this review of that appraisal now provisionally adds three other chemotherapy plus MabThera options. Around ...